Moviprep (Ascorbic Acid, Sodium Ascorbate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macr)

Polyethylene glycol is a large, non‑absorbable polymer that binds water in the intestinal lumen. Together with added electrolytes and ascorbic acid, it creates an osmotic gradient that retains fluid, increases stool volume, and accelerates transit, resulting in thorough evacuation of the bowel.

The dose of Moviprep is determined by the prescribing clinician based on the specific procedure, patient weight, renal function, and institutional protocols. The product is supplied as a powder that is reconstituted with a specified volume of water, and the exact amount to be taken is set by the healthcare provider.

Pregnancy and lactation categories for Moviprep are not definitively established. Because the preparation can cause fluid and electrolyte shifts, it should only be used when the potential benefit outweighs any possible risk. Clinicians should evaluate each case individually and discuss options with the patient.

To order Moviprep, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moviprep uses polyethylene glycol with electrolytes, which generally results in a more balanced fluid and electrolyte profile compared with sodium‑phosphate preparations that can cause larger shifts in serum phosphate and calcium. Both achieve colon cleansing, but Moviprep is often preferred in patients at risk for electrolyte disturbances or renal impairment.

Moviprep should be stored at room temperature, below 25 °C, in its original container. The packaging protects the powder from moisture and light. Keep the product away from excessive heat and humidity, and ensure the container is tightly closed when not in use.

Moviprep is supplied as a powder that must be dissolved in a specified volume of water to create an oral solution. The patient drinks the solution according to the schedule prescribed by the clinician, usually split into two doses taken several hours apart, followed by additional clear fluids as directed.

Serious risks include severe dehydration, significant electrolyte disturbances such as hyponatremia or hypokalemia, acute renal impairment, allergic reactions, and, rarely, colonic perforation. Patients should be monitored for signs of these conditions, and the preparation should be discontinued if severe symptoms develop.

Moviprep is contraindicated in individuals with known or suspected bowel obstruction, severe renal insufficiency, uncontrolled heart failure, or hypersensitivity to any of its components. It should also be avoided in patients who have recently used other strong osmotic laxatives or bowel‑cleansing agents without appropriate medical supervision.